Mankind Pharma opened at ₹2,400.00, in line with its previous close of ₹2,400.00. During today's session, the stock has traded between ₹2,356.20 and ₹2,401.10, with an average traded price of ₹2,372.97. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 4 years ago in Mankind Pharma is now worth
₹ 16,677.00
giving a profit of
₹ 6,677.00 (66.77%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-28.00 (-1.17%)
Day High
₹2,401.10
Day Low
₹2,356.20
Day Open
₹2,400.00
Prev Close
₹2,400.00
Volume
3,29,114
Value Traded
₹78.10 Cr
1W Return
-4.32%
1M Return
4.04%
3M Return
-6.06%
6M Return
14.09%
1Y Return
-3.57%
Market Cap (₹ Cr.)
97,974
PE Ratio
47.90
PB Ratio
6.08
Dividend Yield
0.04%
ROE
11.70%
ROCE
13.78%
Book Value (₹)
394.64
Face Value (₹)
1.00
EPS (TTM)
13.76
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-4.32%
6 Week
-
1 Month
4.04%
3 Month
-6.06%
9 Month
6.64%
Mankind Pharma auditor resigns as subsidiary Bharat Serums enters liquidation
S.R. Batliboi & Co. LLP resigned as statutory auditors of Bharat Serums and Vaccines Ltd on September 28, 2026. Resignation triggered by voluntary liquidation proceedings initiated by shareholders on September 7, 2026. Regulatory rules prohibit liquidators from engaging auditors who served the company in the preceding five years. Auditors completed the FY26 audit report on May 12, 2026, but had not started the FY27 audit.
15 days agoMankind Pharma shareholders approve Anish Bafna as independent director
Mankind Pharma shareholders appointed Anish Vanraj Bafna as an independent director for a five-year term. The special resolution passed with 99.96% of valid votes in favor. Promoters voted unanimously in favor, holding 299,960,612 shares. Total participation rate stood at 95.93% of outstanding shares. No invalid votes were recorded during the remote e-voting process.
26 days agoMankind Pharma receives ESG rating of 68.21 from Niche99 for FY26
Mankind Pharma has received an ESG rating of 68.21 from Niche99 for FY26. The company has been placed in the Leader category under Niche99's ESG rating framework. The rating covers Mankind Pharma's environmental, social, and governance performance for FY26.
28 days agoMankind Pharma to attend three investor conferences in September 2026
Mankind Pharma management to attend three investor conferences in September 2026. Events include Jefferies 5th India Forum in Gurgaon and J.P. Morgan conference in Mumbai. Discussions restricted to public domain information and general business outlook. No unpublished price sensitive information will be shared during meetings.
1mo agoMankind Pharma subsidiary Bharat Serums approved for voluntary liquidation
Bharat Serums and Vaccines, a subsidiary of Mankind Pharma, has received approval for voluntary liquidation. The liquidation process remains subject to pending creditor consent before it can be formally concluded.
1mo agoMankind Pharma completes sale of 100% stake in Broadway Hospitality
Mankind Pharma completed the sale of 100% stake in Broadway Hospitality Services Private Limited. Buyer is AKRK Projects LLP and its partners. Transaction closed on August 31, 2026. Broadway ceased to be a subsidiary from August 31, 2026. Initial disclosure was made on July 11, 2026.
1mo ago| Contract | Days to Expiry | LTP | Change | Change % | Volume | OI | OI Chg % |
|---|---|---|---|---|---|---|---|
| MANKIND OCT FUT | 15 | 2,380.00 | -12.80 | -0.53 | 3,74,500 | 34,48,000 | 3.79 |
| MANKIND NOV FUT | 42 | 2,380.00 | -0.70 | -0.03 | 12,750 | 58,000 | 8.92 |
| MANKIND DEC FUT | 78 | 2,383.00 | -2.20 | -0.09 | 250 | 7,250 | 0.00 |
| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% | |
| ₹351.00 | +1.34% | ₹57,202.26 | 134.86 | -0.69% |
An investment of ₹10,000 made 4 years ago in Mankind Pharma is now worth
₹ 16,677.00
giving a profit of
₹ 6,677.00 (66.77%)
Note: Past profits do not guarantee future returns.
